Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 10/31/2025

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 926 publications

Real-world efficacy and retention of guselkumab in psoriatic arthritis: insights from a 12-month multicenter study.

Real-world efficacy and retention of guselkumab in psoriatic arthritis: insights from a 12-month multicenter study.

Journal: ARP rheumatology
Published: October 01, 2025

Evaluation of Short-to-medium Term Efficacy of Guselkumab and Secukinumab in Overweight and Obese Patients with Moderate to Severe Plaque Psoriasis: A 24-Week Single-center Retrospective Study.

Evaluation of Short-to-medium Term Efficacy of Guselkumab and Secukinumab in Overweight and Obese Patients with Moderate to Severe Plaque Psoriasis: A 24-Week Single-center Retrospective Study.

Journal: Indian journal of dermatology
Published: September 08, 2025

Corticosteroid-Sparing Effects of Treatment With Guselkumab in Patients With Moderately to Severely Active CD: Phase 3 GRAVITI Study Results Through Week 48.

Corticosteroid-Sparing Effects of Treatment With Guselkumab in Patients With Moderately to Severely Active CD: Phase 3 GRAVITI Study Results Through Week 48.

Journal: Gastroenterology & hepatology
Published: September 02, 2025

Successful guselkumab treatment for a psoriasis patient experiencing an adrenal crisis: a case report.

Successful guselkumab treatment for a psoriasis patient experiencing an adrenal crisis: a case report.

Journal: The Journal of dermatological treatment
Published: August 26, 2025

Effectiveness of Brodalumab for Guselkumab-Resistant Pustulotic Arthro-Osteitis in Patients With Palmoplantar Pustulosis: Case Series.

Effectiveness of Brodalumab for Guselkumab-Resistant Pustulotic Arthro-Osteitis in Patients With Palmoplantar Pustulosis: Case Series.

Journal: The Journal of dermatology
Published: August 15, 2025

Predictors of Super-Responder Status to Anti-IL-23 Therapies in Moderate-to-Severe Plaque Psoriasis: A Real-World Monocenter Study.

Predictors of Super-Responder Status to Anti-IL-23 Therapies in Moderate-to-Severe Plaque Psoriasis: A Real-World Monocenter Study.

Journal: Journal of clinical medicine
Published: August 08, 2025

Two-Year Treatment Persistence of Guselkumab vs Other Biologics in Plaque Psoriasis Patients.

Two-Year Treatment Persistence of Guselkumab vs Other Biologics in Plaque Psoriasis Patients.

Journal: Journal of drugs in dermatology : JDD
Published: August 07, 2025

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Journal: The Cochrane database of systematic reviews
Published: August 06, 2025

Practical Considerations for the use of IL-23p19 Inhibitors in Inflammatory Bowel Disease: How to Choose Between Them and Why it Matters?

Practical Considerations for the use of IL-23p19 Inhibitors in Inflammatory Bowel Disease: How to Choose Between Them and Why it Matters?

Journal: Journal of Crohn's & colitis
Published: August 01, 2025

Management of Erythrodermic Psoriasis with Systemic Therapies: A Systematic Review.

Management of Erythrodermic Psoriasis with Systemic Therapies: A Systematic Review.

Journal: American journal of clinical dermatology
Published: July 30, 2025

Long-Term Outcomes of Guselkumab and Risankizumab for the Management of Moderate-to-Severe Psoriasis in the Elderly: Results from a Real-World Retrospective Study.

Long-Term Outcomes of Guselkumab and Risankizumab for the Management of Moderate-to-Severe Psoriasis in the Elderly: Results from a Real-World Retrospective Study.

Journal: Journal of clinical medicine
Published: July 25, 2025

Advanced therapies targeting IL-23: clinical outcomes in ulcerative colitis.

Advanced therapies targeting IL-23: clinical outcomes in ulcerative colitis.

Journal: Expert opinion on biological therapy
Published: July 24, 2025
Showing 1-12 of 926

Last Updated: 10/31/2025